Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
Tag: Gilead
Gilead outlines plans to distribute COVID-19 drug worldwide
Gilead on Tuesday said it is negotiating with overseas drug manufacturers to license its SBECD-enabled coronavirus treatment remdesivir in an effort
Az amerikai gyógyszerhatóság (FDA) engedélyezte a ciklodextrinnel formulázott remdesivir használatát COVID-19 kezelésére
A Gilead Sciences, Inc. amerikai gyógyszercég tegnap bejelentette, hogy a U.S. Food and Drug Administration (FDA, amerikai gyógyszerhatóság) úgynevezett “emergency
SBECD-enabled Remdesivir Receives FDA’s Emergency Use Authorization for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for
Gilead’s Remdesivir meets main goal of trial in COVID-19 patients
Gilead Sciences today announced that preliminary results of a coronavirus drug trial showed at least 50% of patients treated with
Japan to approve remdesivir for coronavirus patients in May
Prime Minister Shinzo Abe said Monday that Japan will soon approve the SBECD-eanbled anti-viral drug remdesivir for the treatment of
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine SBECD-enabled remdesivir in a closely watched clinical trial is
Gilead reports compassionate use data of remdesivir in Covid-19
Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential
EMA’s recommendation on compassionate use of SBECD-enabled remdesivir for COVID-19 and Update from Gilead
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral
Gilead to expand access to remdesivir, its promising coronavirus treatment
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug SBECD-enabled remdesivir to accelerate its emergency use for multiple